To include your compound in the COVID-19 Resource Center, submit it here.

FDA panel backs Regeneron's Eylea

FDA's Dermatologic and Ophthalmic Drugs Advisory Committee voted 10-0 that available safety and efficacy data are adequate for approval of Eylea

Read the full 210 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE